Analysts Offer Insights on Healthcare Companies: Albireo Pharma Inc (NASDAQ: ALBO) and Nucana Plc (NASDAQ: NCNA)

By Ryan Adsit

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Albireo Pharma Inc (NASDAQ: ALBO) and Nucana Plc (NASDAQ: NCNA) with bullish sentiments.

Albireo Pharma Inc (NASDAQ: ALBO)

In a report released today, Liana Moussatos from Wedbush reiterated a Buy rating on Albireo Pharma Inc (NASDAQ: ALBO), with a price target of $63. The company’s shares opened today at $33, close to its 52-week high of $35.53.

According to TipRanks.com, Moussatos is a 4-star analyst with an average return of 9.7% and a 43.4% success rate. Moussatos covers the Healthcare sector, focusing on stocks such as KalVista Pharmaceuticals Inc, Allena Pharmaceuticals Inc, and Catabasis Pharmaceuticals.

Albireo Pharma Inc has an analyst consensus of Strong Buy, with a price target consensus of $63.33.

Nucana Plc (NASDAQ: NCNA)

In a report released today, Boris Peaker from Cowen & Co. assigned a Buy rating to Nucana Plc (NASDAQ: NCNA). The company’s shares opened today at $20.51.

According to TipRanks.com, Peaker is a 4-star analyst with an average return of 8.3% and a 44.4% success rate. Peaker covers the Healthcare sector, focusing on stocks such as SELLAS Life Sciences Group Inc, Madrigal Pharmaceuticals Inc, and Iovance Biotherapeutics Inc.

Nucana Plc has an analyst consensus of Moderate Buy.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.